Clinical Trial Site

Hartford, Connecticut 06112

1 studies enrolling now · 2 studies all time

What they study most

High Cardiovascular Risk, Hypertension, Hypophosphatasia

Studies at this site

• A Prospective Sub-Study of the Global Hypophosphatasia Registry — Recruiting now
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed